A review describes emerging uses of SV2A PET imaging in ALS and other neurodegenerative diseases
Original source
Mapping the Synaptome in Neurodegeneration: Emerging Clinical Applications of SV2A PET Imaging. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human
Population inferred from the title and abstract by Compass.
A review describes positron emission tomography (PET) targeting synaptic vesicle glycoprotein 2A (SV2A) as an evolving way to assess synaptic changes in living people. The reviewed evidence includes amyotrophic lateral sclerosis (ALS), although most published work covers a range of neurodegenerative diseases and uses different tracers and analysis methods.
Why this matters
This may give researchers a way to study synaptic changes and investigate disease progression in ALS. It does not currently change treatment or establish a benefit for people living with ALS.
Limitations and context
This is a review, not a new ALS clinical trial. The field is limited by small cohorts, varied quantification methods and incomplete long-term validation. The source does not provide ALS-specific participant numbers or results, so the clinical usefulness of SV2A PET in ALS remains to be established.